Rapport Therapeutics (RAPP) Profit After Tax (2023 - 2026)
Rapport Therapeutics (RAPP) posted quarterly Profit After Tax of -$19.9 million for Q1 2026, down 4760.42% year-over-year from $427000.0 in Q1 2025, and up 41.09% quarter-over-quarter from -$33.8 million in Q4 2025.
Rapport Therapeutics (RAPP) Profit After Tax (2023 - 2026) Analysis & Trends
Rapport Therapeutics (RAPP) has reported Profit After Tax for 4 consecutive years, with -$19.9 million the latest figure, recorded in Q1 2026.
- In Q1 2026, Profit After Tax fell 4760.42% year-over-year to -$19.9 million; the TTM figure through Mar 2026 stood at -$107.3 million (down 571.67% YoY), while the FY2025 annual figure was -$111.5 million, down 21097.72% from the prior year.
- Profit After Tax rose to -$19.9 million in Q1 2026 per RAPP's latest filing, from -$33.8 million in the prior quarter.
- Across five years, Profit After Tax topped out at $57.4 million in Q4 2024 and bottomed at -$33.8 million in Q4 2025.
- Historically, Profit After Tax has averaged -$11.3 million across 4 years, with a median of -$17.5 million in 2024.
- Annual changes were most pronounced in 2024 — Profit After Tax soared 524.62% — and 2026, when it sank 4760.42%.
- Rapport Therapeutics' Profit After Tax stood at -$13.5 million in 2023, then jumped by 524.62% to $57.4 million in 2024, then slumped by 158.85% to -$33.8 million in 2025, then soared by 41.09% to -$19.9 million in 2026.
- Business Quant data shows RAPP's Profit After Tax at -$19.9 million in Q1 2026, -$33.8 million in Q4 2025, and -$26.9 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | PAT (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 1.10 Bn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 1.30 Bn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | 472.00 Mn |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | -644.37 Mn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 237.01 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | -3,087.27 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 81.49 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 164.49 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | -16.62 Mn |
| 10 | Rapport Therapeutics | 2.27 Bn | 2.27 Bn | - | -57.38 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | -57.38 Mn |
| Mar 31, 2026 | -19.90 Mn |
| Dec 31, 2025 | -33.78 Mn |
| Sep 30, 2025 | -26.93 Mn |
| Jun 30, 2025 | -26.73 Mn |
| Mar 31, 2025 | 427,000.00 |
| Dec 31, 2024 | 57.41 Mn |
| Sep 30, 2024 | -16.95 Mn |
| Jun 30, 2024 | -18.12 Mn |
| Mar 31, 2024 | -22.67 Mn |
| Dec 31, 2023 | -13.52 Mn |
| Sep 30, 2023 | -8.71 Mn |
| Jun 30, 2023 | -6.41 Mn |